FIBROLAX ® Ispaghola Husk seeds (Psyllium)

FIBROLAX ® is a drug based on Ispaghula Husk seeds

THERAPEUTIC GROUP: Laxatives - Mass-forming laxatives

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications FIBROLAX ® Psyllium Seeds

FIBROLAX ® is used in the treatment of occasional episodes of constipation.

Mechanism of action FIBROLAX ® Psyllium Seeds

FIBROLAX ® consisting of the integument of Ispaghula seeds (psyllium seeds), is characterized by the exclusive presence of vegetable fibers, in particular mucilage.

Taken orally, it can pass quickly through the alimentary canal, reaching intact the intestinal environment, where - completely inert to the absorption processes - it holds water in the enteric lumen, forming a gelatinous mass useful to increase the fecal volume.

The fecal mass, supported by the mucilage, can therefore contribute to the stimulation of the peristaltic movements, regulating the intensity and frequency of the evacuations.

Studies carried out and clinical efficacy

PSYLLIUM AND METABOLIC SYNDROME

The metabolic syndrome is a rapidly growing disease in the western population, characterized by hyperglycemia / insulin resistance, dyslipidemia, overweight / obesity and hypertension. The addition of psyllium-derived fibers to the common diet of these patients has proved useful not only for its laxative effects, but also in the reduction of appetite and in the improvement of the lipidemic profile.

FIBROLAX AND CONSTIPATION

Although FIBROLAX appears to be indicated above all in the treatment of episodic constipation, studies have shown that taking this medicine, even in the case of chronic constipation, can guarantee a reduction in abdominal pain, with an improvement in the frequency and consistency of the evacuations.

PSYLLIUM: POSSIBLE ANTI-DIABETIC ROLE

It is known that laxatives, by reducing the intestinal transit time, can inhibit the absorption of active and nutritious ingredients. This characteristic has been tested, with reference to psyllium seeds, for the ability to improve the clinical profile of the diabetic patient, proving to be effective in reducing glycemic and glycosylated hemoglobin levels, while improving HDL cholesterol concentrations. Despite the encouraging results, it would be appropriate to expand the statistics in order to obtain more significant data.

Method of use and dosage

FIBROLAX ® 3.5 gr sachets Ispaghula Husk or 150 gr jar, with 63.64 grams of Ispaghula Husk: the recommended dosage is one sachet or 2 teaspoons, taken after meals, at least 2-3 times a day, for about two or three days.

It is important to take the drug with plenty of water so as to increase the content of the fecal mass as much as possible. To avoid digestive problems it would be advisable not to lie down after taking FIBROLAX ® waiting at least an hour.

Any adjustments to the dosage or the period of administration should be decided by the doctor, also based on the efficacy of the product and the frequency and consistency of the evacuations.

Warnings FIBROLAX ® Psyllium Seeds

The use of FIBROLAX ® is indicated in the resolution of episodes of occasional constipation, not in the treatment of chronic constipation, where the therapy is based on the evaluation and possible correction of the patient's dietary regime.

In order for the Ispaghula tegument to guarantee a correct laxative effect, it is necessary to maintain a high fluid intake during the day and while taking the medicine.

The abuse of laxatives can determine the appearance of hydro-electrolytic decompensation, with dehydration and hypokalemia (at the base of side effects on the nervous and muscular system) and intestinal atony, characterized by reduction of peristalsis and chronic constipation.

Although FIBROLAX ® appears to be a salable drug without a prescription, it would always be advisable to consult your doctor or pharmacist before taking it, especially for patients under the age of 12 or suffering from hypertension and metabolic endocrine disorders.

PREGNANCY AND BREASTFEEDING

As with many laxatives, there are currently no clinical trials useful to understand the safety profile of FIBROLAX ® on the health of the unborn child or newborn, when taken during pregnancy or during the lactation period.

Therefore, it would be preferable to avoid taking FIBROLAX ® during these periods, or to use it only in cases of real need and under strict medical supervision.

Interactions

The laxatives, therefore also FIBROLAX ® are able to accelerate the intestinal transit time, reducing the absorption of nutrients and active ingredients. In this regard it would be useful to resort to the use of laxatives only after at least 2 hours after taking other drugs.

Contraindications FIBROLAX ® Psyllium Seeds

FIBROLAX ® is contraindicated in case of hypersensitivity to the active ingredient or to one of the excipients.

The use of laxatives is also contraindicated in case of intense abdominal pains, nausea, vomiting, diarrhea, gastro-intestinal affections, even with an acute course, dehydration and in case of intestinal obstruction.

Undesirable effects - Side effects

The intestinal distension induced by the mucilage contained in FIBROLAX ® and by the increase in fecal mass may occasionally be associated with cramps, abdominal colic, flatulence and gastrointestinal obstruction. The incidence of these adverse reactions is more frequent in cases of chronic constipation.

Laxative abuse can be associated with diarrhea, hypokalemia, dehydration, reduced intestinal motility and chronic constipation.